Well‑designed clinical pharmacology (including quantitative pharmacology) studies boost the efficiency and success rate of innovative drug R&D. Our Medical Affairs team is committed to delivering scientific, globally‑minded design solutions to empower your drug development. Guided by the principle — “Comprehensive exploration, bold innovation, rigorous validation” — we drive the clinical translation of breakthrough therapies. Led by a 30‑year veteran in Phase I research, we offer expert design, analysis, and planning services:

Phase II/III Protocol Design
Phase I Trials (FIH, SAD, MAD, FE, DDI)
Bioequivalence Studies (high‑variability, narrow therapeutic index, special dosage forms)
Post‑Marketing Studies